Ian J. Neeland

Oct 14, 2024 | ahajournals.org | Ian J. Neeland

Get full access to this articleView all available purchase options and get full access to this article. REFERENCES1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. doi: 10.1056/NEJMoa20321832.

May 20, 2024 | ahajournals.org | Naveed Sattar |Ian J. Neeland |Darren K. McGuire

Just 40 years ago, the prevalence rate of obesity in most high-income countries was <5% to 10%, whereas the prevalence rates of smoking, high blood pressure and high cholesterol levels were much higher. Consequently, rates of myocardial infarction and stroke were substantially higher, and most patients diagnosed with heart failure (HF) had a short life expectancy, many succumbing to disease-related cachexia (Figure).